Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds

Novartis is getting Tourmaline Bio’s pacibekitug, a Phase 3-ready antibody drug in development for atherosclerotic cardiovascular disease (ASCVD). Tourmaline licensed pacibekitug from Pfizer, which remains eligible for milestone payments tied to the progress of the drug. The post Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds appeared first on…

Read More